
Kamada Ltd. KMDA
$ 6.95
-1.56%
Annual report 2024
added 10-25-2025
Kamada Ltd. Deferred Revenue 2011-2025 | KMDA
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 222 K | 589 K | 461 K | 4.93 M | 4.9 M | 1.92 M | 2.92 M | 5.45 M | 8.18 M | 7.27 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.18 M | 222 K | 3.68 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
283 K | $ 11.3 | -10.17 % | $ 12.2 K | - | |
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
3.68 M | $ 4.37 | -1.58 % | $ 28.1 M | ||
|
Axon Enterprise
AXON
|
613 M | $ 755.0 | 0.8 % | $ 57.2 B | ||
|
Caladrius Biosciences
CLBS
|
5.1 M | $ 0.43 | -16.75 % | $ 25.8 M | ||
|
Sorrento Therapeutics
SRNE
|
1.11 M | $ 0.27 | -29.58 % | $ 126 M | ||
|
BeiGene, Ltd.
BGNE
|
187 M | $ 184.71 | 0.49 % | $ 251 B | ||
|
Orchard Therapeutics plc
ORTX
|
959 K | $ 4.93 | 1.02 % | $ 90.8 M | ||
|
Midatech Pharma plc
MTP
|
1.3 M | $ 0.29 | -18.52 % | $ 27.3 M | ||
|
Advaxis
ADXS
|
165 K | $ 0.31 | -9.65 % | $ 45.9 M | ||
|
Heat Biologics, Inc.
HTBX
|
604 K | $ 3.93 | -5.76 % | $ 99.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
2.85 M | $ 6.2 | - | $ 154 M | ||
|
Zymeworks
ZYME
|
32.9 M | $ 6.42 | - | $ 404 M | ||
|
Aeterna Zentaris
AEZS
|
2.19 M | $ 5.72 | 5.93 % | $ 314 M | ||
|
Kadmon Holdings, Inc.
KDMN
|
4.4 M | $ 9.5 | - | $ 1.7 B | ||
|
BioDelivery Sciences International
BDSI
|
1.72 M | $ 2.58 | -4.8 % | $ 255 M | ||
|
Mesoblast Limited
MESO
|
19.5 M | $ 16.73 | 0.12 % | $ 10.9 B | ||
|
Zosano Pharma Corporation
ZSAN
|
26 K | $ 0.56 | 7.23 % | $ 2.72 M | ||
|
Acceleron Pharma Inc.
XLRN
|
541 K | $ 179.68 | - | $ 10.9 B | ||
|
Moderna
MRNA
|
153 M | $ 25.35 | -4.91 % | $ 9.73 B | ||
|
Merus N.V.
MRUS
|
29.9 M | $ 94.9 | 0.32 % | $ 6.09 B | ||
|
Kaleido Biosciences
KLDO
|
498 K | $ 0.29 | -3.69 % | $ 12.4 M | ||
|
Humanigen
HGEN
|
883 K | $ 0.04 | -81.12 % | $ 4.28 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | $ 0.39 | - | $ 26.5 M | ||
|
Celyad Oncology SA
CYAD
|
2.21 M | $ 0.47 | - | $ 12.5 M | ||
|
Nektar Therapeutics
NKTR
|
5.52 M | $ 60.92 | -2.64 % | $ 11.6 B | ||
|
Brickell Biotech
BBI
|
1.8 M | $ 2.11 | -5.38 % | $ 6.06 M | ||
|
Genocea Biosciences
GNCA
|
1.7 M | $ 0.05 | -15.0 % | $ 3.04 M | ||
|
Codiak BioSciences
CDAK
|
13 M | $ 0.06 | -55.98 % | $ 2.15 M | ||
|
Concert Pharmaceuticals
CNCE
|
2.75 M | $ 8.37 | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
240 K | $ 3.17 | 1.93 % | $ 17.4 M | ||
|
Calithera Biosciences
CALA
|
1.55 M | $ 0.37 | -10.95 % | $ 876 K | ||
|
Ocular Therapeutix
OCUL
|
128 K | $ 11.53 | -0.17 % | $ 1.82 B | ||
|
Forma Therapeutics Holdings
FMTX
|
1.24 M | $ 20.01 | - | $ 958 M | ||
|
Oragenics
OGEN
|
14.2 K | $ 1.29 | -2.27 % | $ 2.9 M | ||
|
Arena Pharmaceuticals
ARNA
|
1.11 M | $ 49.55 | -6.81 % | $ 3.04 B | ||
|
Oncolytics Biotech
ONCY
|
927 K | $ 1.22 | 0.83 % | $ 115 M |